← ANALYST RATINGS · TIPRANKS
Shattuck Labs (STTK): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $15.86, the highest $19.00, the lowest $13.00. The average is +192.6% from the last price of $5.42.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.50 → $6.00+9.1% | Hold | +10.7% | Reiterated | 17.10.26on TipRanks 05:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $6.00+9.1% | Hold | +10.7% | Reiterated | 17.10.26on TipRanks 05:07 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $5.50−15.4% | Hold | +1.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $5.50−15.4% | Hold | +1.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Hold | +1.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $5.00−16.7% | Hold | −7.7% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| Name not given | — | $17.00 | Buy | +213.7% | Initiated | 11.10.26on TipRanks Oct 12 05:55 | +2.1%next day −9.8% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $14.00 | Buy | +158.3% | Reiterated | 02.10.26on TipRanks Oct 5 04:07 | −2.3%next day −4.1% · 5 days −12.5% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $15.00 | Buy | +176.8% | Reiterated | 02.10.26on TipRanks 07:35 | −2.3%next day −4.1% · 5 days −12.5% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $17.00 → $19.00+11.8% | Buy | +250.6% | Assigned | 02.10.26on TipRanks 06:30 | −2.3%next day −4.1% · 5 days −12.5% | ↗ |
| Unknown Analyst | Leerink Partners | $16.00 | Buy | +195.2% | Reiterated | 01.10.26on TipRanks 12:11 | +0.1%next day −2.3% · 5 days −18.6% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $14.00 | Buy | +158.3% | Reiterated | 30.09.26on TipRanks 12:45 | +4.5%next day +0.1% · 5 days −19.0% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $18.00 | Buy | +232.1% | Initiated | 24.08.26on TipRanks 06:40 | +5.2%next day +1.7% · 5 days −11.7% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $10.00 → $13.00+30.0% | Buy | +139.9% | Reiterated | 12.08.26on TipRanks Aug 13 08:05 | +4.1%next day −3.0% · 5 days +2.7% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $18.00 | Buy | +232.1% | Reiterated | 12.08.26on TipRanks 08:15 | +4.1%next day −3.0% · 5 days +2.7% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 19:45 | +8.6%next day +2.3% · 5 days −8.8% | ↗ |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Initiated | 27.04.26on TipRanks 07:25 | −0.4%next day −2.0% · 5 days −10.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Shattuck Labs
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.29 at a price of $6.82 (+124.1%); now: $16.00 at $5.42 (+195.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 10 | 6 | 9 | 5 | 9 |
| Buy | 5 | 2 | 2 | 2 | 2 | 1 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.10 (from $-0.16 to $-0.08). Last quarter: $-0.12.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Shattuck Labs
- CEO: Taylor H. Schreiber
- Employees: 40
- 500 West 5th Street, Austin, TX, 78701, US
- www.shattucklabs.com
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗